Ardelyx, Inc. filings document a commercial-stage biopharmaceutical company with U.S. product revenue from IBSRELA and XPHOZAH and development activity centered on tenapanor and NHE3 inhibition. Form 8-K reports cover quarterly operating results, preliminary product sales, cash and investment updates, Regulation FD presentation materials, and other material-event disclosures tied to the company’s commercial and clinical programs.
Ardelyx proxy materials describe annual meeting proposals, director elections, say-on-pay matters, auditor ratification, executive compensation, board structure, and stockholder voting mechanics. Additional current reports record officer appointments, executive transitions, transition and separation agreements, compensatory arrangements, governance matters, and disclosure controls relevant to the company’s public-company reporting obligations.
ARDELYX, INC. (ARDX) reported that Chief Financial Officer Susan Hohenleitner sold 1,558 shares of common stock on 2026-08-21 at a weighted-average price of $3.8569 per share. According to the filing, this was an automatic sell-to-cover triggered by vesting of RSUs to pay withholding taxes, executed in multiple trades between $3.648 and $3.984. After these tax-related sales, she directly holds 227,520 shares of ARDX common stock.
ARDELYX, INC. (ARDX) reported that Senior Vice President and Chief Accounting Officer Joseph James Reilly sold a total of 3,982 shares of common stock on August 21, 2026. According to the disclosure, these sales were an automatic sell-to-cover triggered by the vesting of restricted stock units and were executed solely to cover applicable withholding taxes, at a weighted average price of $3.8569 per share across multiple trades.
ARDELYX, INC. (ARDX) reported that Chief Technical and Quality Officer John E. Bishop sold a total of 19,750 shares of common stock on 2026-08-21 at a weighted average price of $3.8569 per share. According to the company’s disclosure, these shares were sold pursuant to an automatic sell-to-cover feature triggered by the vesting of restricted stock units, and were disposed of solely to cover applicable withholding taxes.
Ardelyx, Inc. (ARDX) reported that Chief Human Resources Officer Brady James Parker sold a total of 15,136 shares of common stock on August 21, 2026. According to the company’s disclosure, these sales were an automatic sell-to-cover related to vesting RSUs, executed solely to cover withholding taxes at a weighted average price of $3.8569 per share across multiple trades.
ARDELYX, INC. (ARDX) reported that Chief Commercial Officer Eric Duane Foster sold a total of 8,562 shares of common stock on 2026-08-21 at a weighted average price of $3.8569 per share. According to the footnote, these sales were an automatic sell-to-cover triggered upon vesting of restricted stock units and were made solely to cover applicable withholding taxes, executed in multiple trades between $3.648 and $3.984 per share.
ARDELYX, INC. (ARDX) reported that Chief Business Officer Mike Kelliher sold a total of 7,758 shares of common stock on 2026-08-21. The sales were executed as an automatic sell-to-cover required by the terms of his restricted stock unit awards, and were made solely to cover applicable withholding taxes upon RSU vesting. The transactions occurred in multiple trades at prices ranging from $3.648 to $3.984 per share, with a weighted average sale price of $3.8569 per share.
ARDELYX, INC. (ARDX) reported that Chief Patient Officer Laura A. Williams sold common stock in multiple transactions on August 21, 2026. A total of 10,739 shares of common stock were sold at a weighted average price of $3.8569 per share, with individual trade prices ranging from $3.648 to $3.984 per share. According to the RSU grant terms, these were automatic sell-to-cover transactions executed upon vesting of restricted stock units, conducted solely to cover applicable withholding taxes.
ARDELYX, INC. (ARDX) reported that President & CEO Michael Raab sold a total of 58,574 shares of common stock on 2026-08-21 in four open-market transactions. According to the disclosure, these sales were an automatic sell-to-cover upon vesting of RSU awards, executed solely to cover withholding taxes, at a weighted average price of $3.8569 per share across trades ranging from $3.648 to $3.984. Raab also has indirect ownership through a living trust and trusts for his children, as noted in the filing, though this entry does not state the share counts for those holdings.
ARDELYX, INC. (ARDX) received a Rule 144 notice stating that Susan Hohenleitner plans to sell 2,650 shares of common stock through Morgan Stanley Smith Barney LLC on or after 08/21/2026, with an indicated aggregate market value of $10,679.50. The shares relate to 5,355 RSUs vesting on 08/19/2026, with sales made pursuant to an automatic sell-to-cover arrangement to satisfy withholding taxes. A prior sale of 1,455 shares for $9,119.21 on 05/21/2026 is also reported. ARDELYX had 249,187,572 shares outstanding as referenced in the notice.
Ardelyx, Inc. (ARDX) is the issuer in a Form 144 notice filed for planned sales of its common stock by officer Mike Kelliher. The notice covers 10,500 shares of common stock, with an approximate aggregate market value of $42,315.00, to be sold through Morgan Stanley Smith Barney LLC on NASDAQ. The shares relate to RSUs vesting on 08/19/2026 and are to be sold solely under an automatic sell-to-cover feature to satisfy applicable withholding taxes. Ardelyx reports 249,187,572 common shares outstanding in connection with this notice.